Paser (Aminosalicylic Acid) - Summary

PASER SUMMARY

PASER granules are a delayed release granule preparation of aminosalicylic acid (p-aminosalicylic acid: 4-aminosalicylic acid) for use with other anti-tuberculosis drugs for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. The granules are designed for gradual release to avoid high peak levels not useful (and perhaps toxic) with bacteriostatic drugs. Aminosalicylic acid is rapidly degraded in acid media; the protective acid-resistant outer coating is rapidly dissolved in neutral media so a mildly acidic food such as orange, apple or tomato juice, yogurt or apple sauce should be used.

PASER is indicated for the treatment of tuberculosis in combination with other active agents. It is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) or in situations when therapy with isoniazid and rifampin is not possible due to a combination of resistance and/or intolerance. When PASER is added to the treatment regimen in patients with proven or suspected drug resistance, it should be accompanied by at least one and preferably two other new agents to which the patient's organism is known or expected to be susceptible.

PASER NEWS HIGHLIGHTS

Media Articles Related to Paser (Aminosalicylic Acid)

How To Differentiate Abdominal Tuberculosis From Lymphomas?
Source: Lymphoma / Leukemia News From Medical News Today [2008.09.24]

Tuberculosis Skin Test (PPD Skin Test)
Source: MedicineNet Rheumatoid Arthritis Specialty [2008.09.02]

Tuberculosis - MIT Creates New Testing And Reporting System, Rewarding Patients Who Take Their Medicine
Source: Compliance News From Medical News Today [2008.06.04]

Tuberculosis
Source: MedicineNet Erythema Nodosum Specialty [2008.01.17]

Extensively Drug-Resistant Tuberculosis (XDR TB)
Source: MedicineNet ICU Psychosis Specialty [2007.05.30]

more>>

Published Studies Related to Paser (Aminosalicylic Acid)

Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. [2007.09]

Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. [2007.07.01]

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. [2006.01]

Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. [2005.06.01]

Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. [2004.12]

more>>

Clinical Trials Related to Paser (Aminosalicylic Acid)

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children [Recruiting]

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease [Recruiting]

The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels [Completed]

Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis [Completed]

Controlled Trial of 4-Aminosalicylic Acid in Patients With Small Bowel Crohn's Disease [Active, not recruiting]

more>>